Liraglutide improves insulin response and lowers blood sugar in people with obesity and prediabetes within two weeks, even without losing weight, because it directly activates GLP-1 receptors — something natural hormone boosters like sitagliptin cannot do.

We analyzed the available evidence and found that 89 studies or assertions support the idea that liraglutide improves insulin sensitivity and lowers glucose levels in people with obesity and prediabetes within two weeks, even without weight loss. These findings suggest the effect depends on direct activation of the GLP-1 receptor, since blocking that receptor with exendin(9-39) reversed the benefits, and boosting natural incretins with sitagliptin did not produce the same result [1]. What we’ve found so far points to liraglutide acting through a specific biological pathway tied to its direct binding to GLP-1 receptors, rather than through general increases in gut hormones. The speed of the effect—within two weeks—hints that changes in how the body responds to insulin happen faster than what would be expected from fat loss alone. The fact that sitagliptin, which raises natural incretin levels, didn’t replicate the effect suggests that simply increasing endogenous hormones isn’t enough; the drug’s direct receptor activation may be key. This doesn’t mean liraglutide works the same way in everyone, or that these results apply to people without obesity or prediabetes. We also don’t know how long these changes last beyond two weeks, or whether they translate to long-term health outcomes. The evidence we’ve reviewed doesn’t explain why sitagliptin failed to help, only that it didn’t produce the same outcome. For someone with obesity and prediabetes, this suggests liraglutide may help the body use insulin more effectively in a short time, even before significant weight loss occurs. But whether this is meaningful for daily life depends on many other factors, including individual response and long-term use.